Answers are grounded in this paper and cite their sources.
This review surveys biotechnological advancements to produce myo-inositol sustainably, highlighting key methods and challenges.
Myo-inositol, a high-value cyclic polyol, is increasingly sought by pharmaceutical, food, feed, and cosmetic industries. This review systematically surveys the latest biotechnological advances poised to replace traditional, high-pollution methods. First, multienzyme cascades that convert renewable carbohydrates─starch, glucose, xylose, cellulose, sucrose─are reviewed, highlighting immobilized reactors, porous microspheres, biomimetic mineralized capsules, and biofilm systems that boost stability, reusability, and space-time yields. Second, microbial cell-factory strategies are examined, covering chassis benchmarking (Escherichia coli, Pichia pastoris, Kluyveromyces marxianus, cyanobacteria), carbon-flux redirection, glucose-glycerol synergistic feeding, and dynamic regulatory circuits. A unified analysis pinpoints recurrent bottlenecks─cofactor imbalance, enzyme thermostability gaps, narrow substrate spectra, product inhibition, and downstream complexity─and distills the targeted fixes discussed in the field, from cofactor regeneration circuits to modular process design. By integrating cutting-edge research with industrial techno-economic indicators, this review offers a comprehensive roadmap for sustainable, cost-competitive myo-inositol biomanufacturing and guides future research toward greener production systems.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: